Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 14, 2023

Busulfan Plus Fludarabine vs Busulfan Plus Cyclophosphamide in Patients With AML Undergoing Haplo-HCT

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
J. Clin. Oncol 2023 Jun 19;[EPub Ahead of Print], Y Ling, L Xuan, N Xu, F Huang, Z Fan, Z Guo, X Xu, H Liu, R Lin, S Yu, H Zhang, H Jin, M Wu, C Liu, X Liang, R Ou, Y Zhang, X Liu, H Qu, X Zhai, J Sun, Y Zhao, Q Liu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading